SCHEDULE 13G/A: Perceptive Advisors Discloses 1.6% Passive Stake in Verrica Pharmaceuticals

Perceptive Advisors LLC and its affiliated entities have filed an amended Schedule 13G, disclosing a 1.6% beneficial ownership stake in Verrica Pharmaceuticals, Inc., holding 1,481,481 shares through pre-funded warrants.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. are the reporting persons in this Schedule 13G Amendment No. 10.
• The filing pertains to the Common Stock, $0.0001 par value per share, of Verrica Pharmaceuticals, Inc.
• The reporting persons collectively beneficially own 1,481,481 shares of Verrica Pharmaceuticals' Common Stock.
• This ownership represents 1.6% of the total class of securities outstanding.
• The ownership percentage is calculated based on 92,490,993 shares of Common Stock outstanding as of April 16, 2025, as reported by the Issuer.
• The shares are held through the exercise of Pre-Funded Warrants.
• Perceptive Advisors serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This filing is a routine regulatory disclosure of beneficial ownership and does not contain performance metrics, strategic updates, or forward-looking statements that would typically influence sentiment. It is a neutral, factual report.

Positives

• The disclosure of a 1.6% stake by a notable investment firm like Perceptive Advisors may signal institutional confidence in Verrica Pharmaceuticals, Inc.

Future Outlook

NA

Management Comments

• The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment firm in a pharmaceutical company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact of the investment.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership by Perceptive Advisors and its affiliates, which may be viewed as a positive signal of investor interest.

Key Dates

Keywords

Verrica Pharmaceuticals, Perceptive Advisors, Joseph Edelman, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Pharmaceuticals, Biotechnology